MTOR and idiopathic pulmonary fibrosis: Despite the promising improvements in safety and efficacy offered by the new class of mTOR inhibitors like Gedatolisib over existing drugs in breast cancer (74), if repurposed to IPF, chronic PI3K inhibition may still lead to unexpected compensatory activation of alternative pro-fibrotic pathways such as Mitogen-Activated Protein Kinase (MAPK) signaling (97).